TATA Health International Holdings Limited
TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

FURTHER DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS, THE 2024 INTERIM RESULTS AND THE 2024 ANNUAL RESULTS AND FURTHER DELAY IN DESPATCH OF THE 2023 ANNUAL REPORT, THE 2024 INTERIM REPORT AND THE 2024 ANNUAL REPORT AND DELAY IN PUBLICATION OF THE 2025 INTERIM RESULTS AND DELAY IN DESPATCH OF THE 2025 INTERIM REPORT AND CONTINUED SUSPENSION OF TRADING

Reference is made to the announcements made by the board (the "**Board**") of directors ("**Director(s)**") of TATA Health International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 25 March 2024, 2 April 2024, 12 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 12 July 2024, 31 July 2024, 12 August 2024, 13 September 2024, 30 September 2024, 4 October 2024, 14 October 2024, 14 November 2024, 13 December 2024, 3 January 2025, 13 January 2025, 13 February 2025, 14 March 2025, 31 March 2025, 14 April 2025, 15 May 2025, 11 July 2025, 14 July 2025, 22 July 2025 and 25 July 2025 (collectively, the "**Announcements**") in relation to, among others, the initial resumption guidance and additional resumption guidance imposed by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on the Company pursuant to, among other things, Rules 13.09(2)(a), 13.24A, 13.46(2) and 13.49(1) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on the Stock Exchange and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

DELAY IN PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 (THE "2023 ANNUAL RESULTS"), THE INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 (THE "2024 INTERIM RESULTS"), THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 (THE "2024 ANNUAL RESULTS") AND THE INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 (THE "2025 INTERIM RESULTS") AND DELAY IN DESPATCH OF THE ANNUAL REPORT FOR THE 2023 ANNUAL RESULTS (THE "2023 ANNUAL REPORT"), THE INTERIM REPORT FOR THE 2024 INTERIM RESULTS (THE "2024 INTERIM REPORT"), THE ANNUAL REPORT FOR THE 2024 ANNUAL RESULTS (THE "2024 ANNUAL REPORT") AND THE INTERIM REPORT FOR THE 2025 INTERIM RESULTS (THE "2025 INTERIM REPORT")

The Board wishes to inform the Shareholders that there will be a further delay in publication of the 2023 Annual Results, the 2024 Interim Results and the 2024 Annual Results and despatch of the 2023 Annual Report, the 2024 Interim Report and the 2024 Annual Report as there is a recent change in the composition of the management of the Company, and in particular, more time is required for the new finance and/or compliance personnel to, among others, get familiarise with all the outstanding audit issues of the Group and follow up with the Company's auditor on the audit progress so as to complete the audit work for the 2023 Annual Results. Accordingly, additional time is required for the Company to finalise the 2023 Annual Results, the 2024 Interim Results and the 2024 Annual Results.

Due to the delay in the publication of the 2023 Annual Results, there is a delay in publication of the 2025 Interim Results and the despatch of the 2025 Interim Report.

Pursuant to Rule 13.49(6) of the Listing Rules, the Company is required to publish the 2025 Interim Results no later than two months after the end of the reporting period (i.e. on or before 31 August 2025). Pursuant to Rule 13.48(1) of the Listing Rules, the Company is required to despatch the 2025 Interim Report to the Shareholders not later than three months after the end of the reporting period (i.e. on or before 30 September 2025). Due to the delay in the publication of the 2025 Interim Results, it is expected that there may be a possible delay in the despatch of the 2025 Interim Report. The delay in publication of the 2025 Interim Results and the possible delay in despatch of the 2025 Interim Report would constitute non-compliance with Rule 13.49(6) and Rule 13.48(1) of the Listing Rules, respectively.

Based on the current audit progress, it is expected that the dates of publication of (i) the 2023 Annual Results will be postponed to a date on or before 10 September 2025; (ii) the 2024 Interim Results will be postponed to a date on or before 15 September 2025; (iii) the 2024 Annual Results will be postponed to a date on or before 19 September 2025; and (iv) the 2025 Interim Results will be postponed to a date on or before 23 September 2025.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024, and will remain suspended pending, among others, the release of announcements for each of the 2023 Annual Results, the 2024 Interim Results, the 2024 Annual Results and the 2025 Interim Results. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Non-executive Director

Hong Kong, 3 September 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and three independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.